Search bioRxiv⌕ Search

Biology subjects

Isoda, N.

Publications and source records attributed to Isoda, N..

3 recordsLinked to original sources

A cattle-derived human H5N1 isolate suppresses innate immunity despite efficient replication in human respiratory organoids

The H5N1 high pathogenicity avian influenza virus (HPAIV) of clade 2.3.4.4b, which spreads globally via wild birds, has become a major public health concern because it can infect a variety of mammals, including humans. In 2024, infection of dairy cattle with H5N1 HPAIV clade 2.3.4.4b was confirmed in the United States, and subsequent human cases were reported. Although these viruses are highly pathogenic in animal models, human infections have generally been mild, revealing a striking discrepancy. Here, we characterized the cattle-derived human H5N1 isolate A/Texas/37/2024 (TX37-H5N1) using three-dimensional human respiratory organoids derived from induced pluripotent stem (iPS) cells. Despite efficient replication, TX37-H5N1 induced minimal interferon and inflammatory cytokine responses. Bulk and single-cell RNA sequencing revealed reduced STAT1-mediated transcriptional activity in TX37-H5N1-infected organoids compared to the historic H5N1 human isolate A/Vietnam/1203/2004. These findings suggest that TX37-H5N1 fails to trigger the strong innate responses, including robust cytokine production, that are typically associated with severe H5N1 disease and are thought to contribute to cytokine storm-medicated pathogenesis. This attenuated response may help explain the discrepancy between the high pathogenicity of TX37-H5N1 in animal models and its mild clinical presentation in humans. While zoonotic influenza risk is often assessed using cell lines or animal models, our study highlights the value of using human respiratory organoids to evaluate human-specific virus-host interactions. This platform provides a complementary tool for assessing the risk of emerging avian influenza viruses. HighlightsO_LIHuman respiratory organoids were used to model zoonotic B3.13 H5N1 infections. C_LIO_LIA cattle-derived human isolate, TX37-H5N1, replicated more efficiently than historical VN1203-H5N1. C_LIO_LITX37-H5N1 suppressed STAT-IRF-mediated innate immune responses. C_LIO_LITX37-H5N1 was sensitive to baloxavir and oseltamivir but less sensitive to favipiravir. C_LIO_LIHuman respiratory organoids offer a complementary platform for zoonotic influenza risk assessment. C_LI In briefOur study used human iPSC-derived respiratory organoids to investigate the mild clinical presentation of zoonotic B3.13 H5N1 viruses. We found that TX37-H5N1 replicates efficiently but suppresses innate immune responses, providing mechanistic insight into species-specific pathogenesis and highlighting the utility of human organoids for zoonotic risk assessment.

microbiology↗

Evaluation of therapeutic effect of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model

Since 2020, high pathogenicity avian influenza virus (HPAIV) infections in wild birds have been frequently reported. Because HPAIV infection has occasionally caused outbreaks in captive rare birds, application of antiviral drugs for treatment purposes against them has been considered from the perspective of conservation medicine. In this study, the therapeutic efficacy of baloxavir marboxil (BXM) was evaluated using a duck model to help establish the post-infection treatment for rare birds. Sixteen four-week-old ducks were divided into four groups and intranasally inoculated with the HPAIV strain A/crow/Hokkaido/0103B065/2022 (H5N1). BXM was orally administered once daily at doses of 12.5, 2.5, 0.5, and 0 mg/kg to each of the four groups from 2 to 6 days post-infection. Blood samples were collected at 2, 8, and 24 hours after the initial BXM administration to measure the plasma concentrations of its active form, baloxavir acid (BXA). All ducks were monitored until 14 days post-infection, and their oral and cloacal swabs were collected for virus recovery. All eight ducks administered with 12.5 or 2.5 mg/kg of BXM survived, demonstrating a significant reduction in virus recovery compared to the 0 mg/kg group. Pharmacokinetic/pharmacodynamic (PK/PD) analysis of BXA suggested that parameters such as Cmax and AUC0-24hr were correlated with the suppression of virus shedding. These findings demonstrated that BXM administration within 48 hours post-HPAIV infection in ducks effectively reduced mortality and virus shedding. The comparison of PK parameters may help estimate efficient BXM dosing strategies in rare birds. HighlightBXM prevented death of HPAIV-infected ducks when given within 48 hr of inoculation. Doses of 2.5 mg/kg rapidly suppressed and eliminated infectious virus shedding. AUC0-24hr and Cmax correlated with suppression of virus shedding.

microbiology↗